StockTake: Imagion starts MagSense manufacturing ahead of breast cancer trial

Imagion Biosystems (ASX:IBX) has started manufacturing its MagSense HER-2 imaging agent ahead of a Phase 2 breast cancer trial later this year. 

The company is also preparing an Investigational New Drug Application with the FDA in America, alongside work starting on Imagion’s AI imaging protocol optimisation collaboration with Siemens and Wayne State University.

Watch the video to learn more.

This video was developed in collaboration with Imagion Biosystems, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.